BRIEF REPORT
. Although MTX has been used in the treatment of moderate to severe psoriasis for the last 60 years, a close evaluation of adverse effects and related risk factors of MTX therapy has not been performed. In spite of growing concerns about cumulative toxicity, there are no detailed data for complications associated with an increased cumulative dose of MTX. In this study, we examined the laboratory adverse effects and clinical risk factors including cumulative dose or treatment duration related to laboratory test abnormalities in psoriasis patients treated with MTX in daily practice. Elevated transaminases were found in about 20%∼30% of patients treated with a typical dose of MTX, which was consistent with former studies 3, 5, 6 , but signs of myelosuppression such as pancytopenia, which are well-recognized adverse effects of MTX, were not observed. We presume that hematologic toxicity can be prevented in certain psoriasis patients without significant risk factors, particularly renal impairment, lack of folate supplementation, and medication errors 7 .
Our data illustrated that if patients continued MTX therapy for approximately 1 year, which could be a part of the rotational psoriasis therapy 8 for moderate to severe psoriasis, the mean cumulative dose was approximately 0.5 g. According to our findings, the use of MTX for up to 1 year in clinical practice does not require liver biopsy for hepatotoxicity monitoring 7, 9 .
Overall, our study suggests no statistically significant risk factors for laboratory abnormalities in psoriatic patients treated with MTX (Table 2) . Interestingly, our results suggest no significant association between cumulative MTX dose and transaminitis (Table 2) . Treatment duration was also not associated with increased liver enzymes. These findings corroborate previous reports 10 . In addition, advanced age, duration of psoriasis, and comorbidities were not clinical risk factors for the development of adverse events. Although MTX therapy is considered relatively safe in laboratory controlled psoriatic patients, our study provides evidence that typical MTX therapy can result in clinically significant liver enzyme abnormalities independent of cumulative dose and treatment duration. Therefore, when using MTX, thorough and regular monitoring for identifying MTX-related toxicity should be performed for every patient, regardless of health status.
